SimplyTest Oral Health Launches Implant-Specific Salivary Test

SALT LAKE CITY--(BUSINESS WIRE)--SimplyTest®, a leader in salivary screening solutions, today announced the launch of SimplyTest Oral Health-IMPLANT, a new molecular test designed to detect microbial species linked to peri-implant disease and implant failure. This test is the latest addition to the company’s growing SimplyTest Oral Health line, which also includes SimplyTest Oral Health-PERIO and others.

According to a comprehensive review published in Cureus in 2022, infection is the most frequent and preventable cause of dental implant failure. SimplyTest Implant is engineered to detect eight high-risk pathogens, which include Porphyromonas gingivalis (Pg), Treponema denticola (Td), Tannerella forsythia (Tf), Prevotella intermedia (Pi), Fusobacterium nucleatum (Fn), Fusobacterium animalis (Fa), Candida albicans (Ca) and Pseudomonas aeruginosa (Pa). These organisms are recognized contributors to inflammation, tissue degradation and systemic immune response, often without visible early symptoms.

“Microbial infections are a major cause of implant-related complications,” said Joel Peek, Ph.D., SimplyTest Founder and Scientific Advisory Board Chair. “With SimplyTest Oral Health-IMPLANT, clinicians now have a fast, noninvasive way to identify the microbial risks before failure occurs. It's another step forward in our mission to elevate patient care through precision-based oral health solutions.”

Designed for chairside use or at-home collection, IMPLANT leverages a proprietary saliva preservation and analysis system. Results are delivered within 24 to 48 hours after the sample is received at the lab via a secure clinical portal, with pathogen-specific insights to support diagnostic conversations and treatment planning.

“The SimplyTest Oral Health line is part of a broader effort to redefine the standard of care in dentistry and systemic healthcare by empowering providers with tools that reveal the root causes of oral and systemic conditions,” said Justin Hunt, CEO of Spectrum Health Science. “The IMPLANT test expands our platform’s reach to support preventative implant care, surgical planning and cost-efficient treatment, which are key concerns for both clinicians and care organizations. It’s a strong example of how SimplyTest equips providers with timely insights that improve patient outcomes and help reduce avoidable expenses.”

Healthcare professionals can learn more about the IMPLANT offering and request materials at https://www.simplytest.solutions.

About SimplyTest

SimplyTest® is redefining the starting point of care through next-generation salivary science. The SimplyTest platform delivers fast, noninvasive screenings that empower health care providers, functional medicine practitioners and dental professionals to detect microbial risks earlier, personalize treatment with precision and connect oral health to whole-body outcomes. Built on the belief that better diagnostics lead to better outcomes, SimplyTest is advancing a smarter, data-driven model of dentistry where early insight is the first step in personalized care. To learn more, visit https://www.simplytest.solutions.